Alpha Teknova (TKNO) Projected to Post Quarterly Earnings on Wednesday

Alpha Teknova (NASDAQ:TKNO) will likely be announcing its Q1 2026 results after the market closes on Wednesday, May 6th. Analysts expect the company to announce earnings of ($0.0926) per share and revenue of $10.2260 million for the quarter. Investors may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Wednesday, May 6, 2026 at 6:00 PM ET.

Alpha Teknova (NASDAQ:TKNO) last announced its earnings results on Thursday, February 26th. The company reported ($0.09) EPS for the quarter, hitting the consensus estimate of ($0.09). The company had revenue of $9.98 million for the quarter, compared to analysts’ expectations of $9.62 million. Alpha Teknova had a negative return on equity of 23.32% and a negative net margin of 42.59%.

Alpha Teknova Trading Up 3.5%

Alpha Teknova stock traded up $0.13 during mid-day trading on Tuesday, hitting $3.72. The stock had a trading volume of 37,377 shares, compared to its average volume of 195,918. The stock has a 50-day simple moving average of $2.78 and a two-hundred day simple moving average of $3.62. The stock has a market capitalization of $199.27 million, a PE ratio of -11.26 and a beta of 0.47. Alpha Teknova has a 12 month low of $1.91 and a 12 month high of $7.48. The company has a current ratio of 4.58, a quick ratio of 3.64 and a debt-to-equity ratio of 0.19.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Alpha Teknova in a research report on Monday, April 20th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $8.00.

Insider Activity at Alpha Teknova

In other Alpha Teknova news, CEO Stephen Gunstream purchased 26,000 shares of the stock in a transaction dated Friday, March 6th. The stock was bought at an average price of $2.15 per share, for a total transaction of $55,900.00. Following the transaction, the chief executive officer directly owned 269,497 shares in the company, valued at $579,418.55. This represents a 10.68% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. 12.50% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Alpha Teknova

Several institutional investors have recently modified their holdings of TKNO. Balyasny Asset Management L.P. boosted its holdings in Alpha Teknova by 19.5% during the second quarter. Balyasny Asset Management L.P. now owns 1,000,484 shares of the company’s stock worth $4,912,000 after buying an additional 163,526 shares during the last quarter. Geode Capital Management LLC grew its position in shares of Alpha Teknova by 64.4% during the 2nd quarter. Geode Capital Management LLC now owns 298,850 shares of the company’s stock worth $1,468,000 after buying an additional 117,016 shares during the period. Bank of America Corp DE grew its position in shares of Alpha Teknova by 3.3% during the 2nd quarter. Bank of America Corp DE now owns 229,429 shares of the company’s stock worth $1,126,000 after buying an additional 7,256 shares during the period. Massar Capital Management LP grew its position in shares of Alpha Teknova by 185.7% during the 2nd quarter. Massar Capital Management LP now owns 200,000 shares of the company’s stock worth $982,000 after buying an additional 130,000 shares during the period. Finally, Goldman Sachs Group Inc. grew its position in shares of Alpha Teknova by 68.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 90,595 shares of the company’s stock worth $470,000 after buying an additional 36,763 shares during the period. Institutional investors and hedge funds own 13.81% of the company’s stock.

Alpha Teknova Company Profile

Alpha Teknova, Inc (NASDAQ: TKNO) is a life science tools and reagents company that develops, manufactures and distributes proprietary products to support research, drug discovery and biomanufacturing. Its offerings target academic institutions, pharmaceutical and biotechnology firms, and diagnostic developers, with a focus on high-purity reagents and optimized workflows designed to accelerate molecular biology and protein science applications.

The company’s portfolio includes molecular biology reagents, cell culture buffers, in vitro translation kits, custom recombinant proteins, high-throughput screening buffers and other specialized formulations.